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ORIGINAL ARTICLE
The MLL recombinome of acute leukemias in 2017
C Meyer1, T Burmeister2, D Gröger2, G Tsaur3, L Fechina3, A Renneville4, R Sutton5, NC Venn5, M Emerenciano6, MS Pombo-de-Oliveira6,
C Barbieri Blunck6, B Almeida Lopes6, J Zuna7, J Trka7, P Ballerini8, H Lapillonne8, M De Braekeleer9,{, G Cazzaniga10, L Corral Abascal10,
VHJ van der Velden11, E Delabesse12, TS Park13, SH Oh14, MLM Silva15, T Lund-Aho16, V Juvonen17, AS Moore18, O Heidenreich19,
J Vormoor20, E Zerkalenkova21, Y Olshanskaya21, C Bueno22,23,24, P Menendez22,23,24, A Teigler-Schlegel25, U zur Stadt26, J Lentes27,
G Göhring27, A Kustanovich28, O Aleinikova28, BW Schäfer29, S Kubetzko29, HO Madsen30, B Gruhn31, X Duarte32, P Gameiro33,
E Lippert34, A Bidet34, JM Cayuela35, E Clappier35, CN Alonso36, CM Zwaan37, MM van den Heuvel-Eibrink37, S Izraeli38,39,
L Trakhtenbrot38,39, P Archer40, J Hancock40, A Möricke41, J Alten41, M Schrappe41, M Stanulla42, S Strehl43, A Attarbaschi43,
M Dworzak43, OA Haas43, R Panzer-Grümayer43, L Sedék44, T Szczepański45, A Caye46, L Suarez46, H Cavé46 and R Marschalek1
Chromosomal rearrangements of the human MLL/KMT2A gene are associated with infant, pediatric, adult and therapy-induced
acute leukemias. Here we present the data obtained from 2345 acute leukemia patients. Genomic breakpoints within the MLL gene
and the involved translocation partner genes (TPGs) were determined and 11 novel TPGs were identified. Thus, a total of 135
different MLL rearrangements have been identified so far, of which 94 TPGs are now characterized at the molecular level. In all, 35
out of these 94 TPGs occur recurrently, but only 9 specific gene fusions account for more than 90% of all illegitimate
recombinations of the MLL gene. We observed an age-dependent breakpoint shift with breakpoints localizing within MLL intron 11
associated with acute lymphoblastic leukemia and younger patients, while breakpoints in MLL intron 9 predominate in AML or older
patients. The molecular characterization of MLL breakpoints suggests different etiologies in the different age groups and allows the
correlation of functional domains of the MLL gene with clinical outcome. This study provides a comprehensive analysis of the MLL
recombinome in acute leukemia and demonstrates that the establishment of patient-specific chromosomal fusion sites allows the
design of specific PCR primers for minimal residual disease analyses for all patients.
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INTRODUCTION
Chromosomal rearrangements involving the human MLL gene are
recurrently associated with the disease phenotype of acute
leukemias.1,2 The presence of distinct MLL rearrangements is an
independent dismal prognostic factor, while very few MLL
rearrangements display either a good or an intermediate
outcome.3,4 It became also clear from recent studies that the
follow-up of patients during treatment and therapy adjustment
based on minimal residual disease (MRD) monitoring has a very
strong impact on outcome.5–7 For this purpose, we established a
diagnostic network that allowed different study groups and
clinical centers to obtain genomic MLL breakpoint sequences that
can be directly used for quantifying MRD levels in patients. The
current work flow to identify MLL rearrangements includes a
prescreening step (cytogenetic analyses,8,9 split-signal fluores-
cence in situ hybidization10–12 or reverse-transcription PCR) in
combination with long-distance inverse PCR that was performed
on small amounts (~1 μg) of isolated genomic DNA.13 This allowed
us to readily identify reciprocal translocations, complex chromo-
somal rearrangements, gene internal duplications, deletions or
inversions on chromosome 11q, and MLL gene insertions into
other chromosomes, or vice versa, the insertion of partner
chromosome material into the MLL gene located at 11q23.
To gain insight into the frequency of distinct MLL rearrange-
ments, all prescreened samples of infant, pediatric and adult
leukemia patients were sent for analysis to the Frankfurt
Diagnostic Center of Acute Leukemia (DCAL) after cytogenetic
prescreening. All prescreened MLL rearrangements were success-
fully analyzed at the Frankfurt DCAL, and patient-specific MLL
fusion sequences for MRD monitoring were obtained.
MATERIALS AND METHODS
Patient material
Genomic DNA was isolated from bone marrow and/or peripheral blood
samples of leukemia patients and sent to the DCAL (Frankfurt/Main,
Germany). Patient samples were obtained from different study groups (the
AMLCG-study group, Munich; the GMALL study group, Berlin; Polish
Pediatric Leukemia and Lymphoma Study Group; Zabrze; I-BFM network)
and diagnostic centers in Europe (Aarhus, Berlin, Barcelona, Bordeaux,
Bratislava, Brest, Bristol, Catania, Copenhagen, Ekaterinburg, Frankfurt,
Giessen, Granada, Graz, Grenoble, Haifa, Hamburg, Hanover, Heidelberg,
Jena, Jerusalem, Kiel, Lille, Lisbon, Madrid, Minsk, Montpellier, Monza,
Moscow, Munster, Munich, Nancy, Nantes, Newcastle upon Tyne, Olomouc,
Padua, Paris, Porto, Prague, Reims, Rotterdam, Strasbourg, Tampere, Tel
Hashomer, Toulouse, Turku, Ulm, Valenciennes, Vienna, Zabrze and Zurich)
or centers located outside of Europe (Adelaide, Boston, Brisbane, Buenos
Aires, Hong Kong, Houston, Rio de Janeiro, Seoul, Sydney and Tohoku),
where acute leukemia patients are enrolled in local study groups. Informed
consent was obtained from all patients or patients’ parents/legal
guardians, and control individuals.
Long distance inverse PCR experiments
All DNA samples were treated and analyzed as described.13–16 Briefly, 1 μg
genomic patient DNA was digested with restriction enzymes and re-ligated
to form DNA circles before long-distance inverse PCR analyses. Restriction
polymorphic PCR amplimers were isolated from the gel and subjected to
DNA sequence analyses to obtain the patient-specific fusion sequences.
This genomic DNA fusion sequence is idiosyncratic for each leukemia
patient and was made available to the sender of the DNA sample. The
average processing time was around 5 working days.
Data evaluation and statistical analyses
All clinical and experimental patient data were implemented into a
database program (FileMaker Pro, FileMaker Inc., Santa Clara, CA, USA) for
further analysis. Information about all individual patients was used to
compare all defined subgroups and to perform statistical analyses to
retrieve important information or significant correlations. χ2-tests were
performed to identify significant deviations from mean values.
Nomenclature
We are well aware about all the changes in the HUGO gene nomenclature
over the past years. However, for the readability of the text, we use the
following gene nomenclature throughout the text: MLL (KMT2A); AF4
(AFF1); LAF4 (AFF3); AF5 (AFF4); ENL (MLLT1); AF9 (MLLT3); AF6 (MLLT4); AF17
(MLLT6); AF10 (MLLT10); and AF1Q (MLLT11).
RESULTS
The study cohort
To analyze the recombinome of the human MLL gene, 2381
prescreened acute leukemia samples were obtained from the
above-mentioned centers from 2003 to 2016. In all cases, we first
used PCR experiments combined with sequence analysis to
diagnose the direct MLL fusion allele, and in case of failure or
having a complex rearrangement, the reciprocal MLL fusion allele
was analyzed. Successful analysis could be performed for all
patient samples. In 31 cases we were only able to characterize the
reciprocal MLL fusion allele to guarantee subsequent MRD
experiments. Complete data were available on 2345/2381 cases
(gender, age at diagnosis, disease type and subtype, or informa-
tion about de novo or secondary leukemia). Genetic and clinical
information of these 2345 patients are summarized in Table 1. The
36 excluded cases had the following MLL rearrangements: 9 ×
MLL–AF9; 8 × MLL–AF4; 4 × MLL–ENL; 4 × MLL–AF10; 3 × MLL–AF6;
2 × MLL–AF17; 2 × MLL–EPS15; 1 × MLL–GAS7; 1 × MLL–
LOC100128568; 1 × MLL–CREBBP; and 1 × MLL–PTD. The exclusion
of these 36 patients did not affected with the general conclusions
made in this study.
Age distribution according to clinical subtypes
We first analyzed our cohort according to the age at diagnosis. As
displayed in Figure 1, the age distribution is quite similar to the
expected distributions known from other cancer registries. MLL-r
acute lymphoblastic leukemia (ALL) incidence has a peak in the
first 2 years, then declines during the pediatric and young adult
phase and then steadily increases again with age. A similar picture
was observed with MLL-r acute myeloid leukemia (AML) patients,
however, missing the postnatal peak seen for infant ALL. For the
purpose of our study we separated our cohort into an ‘infant acute
leukemia cohort’ (0.03–12 months; n= 876: 692 ALL, 160 AML and
24NA) (not annotated), a ‘pediatric acute leukemia group’
(412 months–18 years; n= 671: 313 ALL, 339 AML and 19NA)
and an ‘adult acute leukemia patient’ group (418 years; n= 798:
415 ALL, 373 AML and 10NA). As shown in Figure 1, we also added
information about therapy-induced leukemia (n= 110). Fifty-three
patients could not be categorized into ‘ALL’ or ‘AML’ because they
received other diagnoses (mixed lineage leukemia (MLL) = 38,
myelodysplastic syndrome= 7 and lymphoma= 4), or because we
had no information from the corresponding center (unknown
disease type = 4).
Identification of MLL rearrangements and their distribution in
clinical subgroups
The most frequent MLL rearrangements in these six subgroups
were summarized in Figure 2. Infant ALL (n= 692) displayed 338
AF4, 113 AF9, 154 ENL, 39 AF10, 1 AF6 and 16 EPS15 gene fusions.
Additional 31 MLL rearrangements were identified (9p13.3,
11q23.3, ACER, AF1Q, LAF4, AF5, BTBD18, CLTA, DCP1A, EEFSEC, 14
cases (NA) with no der(11) and only a reciprocal fusion allele,
PICALM, PRPF19 and TNRC18).
Infant AML (n= 160) was represented by 4 AF4, 40 AF9, 2 ENL, 43
AF10, 24 ELL, 2 AF6 and 1 EPS15 gene fusion. Another 44 MLL
rearrangements have been characterized (11q24, ABI1, ABI2, AF1Q,
FLNA, FNBP1, GAS7, KIAS1524, MYO1F, 14 cases (NA) with no der
(11) and only a reciprocal fusion allele, NEBL, NRIP3, PICALM, SEPT5,
SEPT6 and SEPT9).
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Table 1. Overview about all investigated TPGs
# Direct TPG Infant Pediatric Adult Total
ALL AML Other ALL AML Other ALL AML Other
1 AFF1/AF4 338 4 10 139 3 10 332 3 — 839
2 MLLT3/AF9 113 40 5 56 132 3 9 90 1 449
3 MLLT1/ENL 154 2 4 56 21 1 50 14 — 302
4 MLLT10/AF10 39 43 2 12 66 1 1 33 — 197
5 PTD — — — — 6 — 1 98 2 107
6 ELL — 24 1 — 24 — 1 45 2 97
7 MLLT4/AF6 1 2 — 16 28 — 9 38 1 95
8 EPS15 16 1 1 6 5 — 4 5 — 38
9 MLLT11/AF1Q 1 13 — — 7 — — 2 — 23
10 no der(11) 14 6 1 3 5 2 31
11 SEPT6 — 5 — — 10 — — 2 — 17
12 MLLT6/AF17 — — — 1 2 — — 11 — 14
13 SEPT9 — 2 — — 5 — — 6 — 13
14 AFF3/LAF4 3 — — 5 — — — — — 8
15 TET1 — — — — 1 — 2 3 — 6
16 11q23.3 1 — — — 1 — 2 1 — 5
17 SEPT5 — 1 — 1 2 — — 1 — 5
18 ABI1 — 2 — — 2 — — — — 4
19 KNL1 — — — — 2 — — — 2 4
20 MAML2 — — — 2 — — 1 — 1 4
21 MYO1F — 3 — — 1 — — — — 4
22 PICALM 1 1 — 1 — — — 1 — 4
23 TNRC18 1 — — 2 — — 1 — — 4
24 FLNA — 2 — — 1 — — — — 3
25 NEBL 1 1 — — 1 — — — — 3
26 ACTN4 — — — — 1 — 1 — — 2
27 AFF4/AF5 2 — — — — — — — — 2
28 BTBD18 2 — — — — — — — — 2
29 CBL — — — 1 — — — 1 — 2
30 CEP170B — — — — — — — 2 — 2
31 CREBBP — — — — — 2 — — — 2
32 DCP1A 1 — — — 1 — — — — 2
33 FOXO3A — — — 2 — — — — — 2
34 KIAS1524 — 2 — — — — — — — 2
35 SEPT11 — — — 1 1 — — — — 2
36 ABI2 — 2 — — — — — — — 2
37 ACACA — — — — 1 — — — — 1
38 ACER1 1 — — — — — — — — 1
39 AKAP13 — — — — — — — 1 — 1
40 AP2S2 — — — — — — — 1 — 1
41 ARHGAP26 — — — — 1 — — — — 1
42 ARHGEF12 — — — — — — — 1 — 1
43 ARHGEF17 — — — — 1 — — — — 1
44 BCL9L — — — 1 — — — — — 1
45 BUD13 — — — — 1 — — — — 1
46 C2CD3 — — — — — — — 1 — 1
47 CASP8AP2 — — — — — — — 1 — 1
48 CEP164 — — — — — — 1 — — 1
49 CLTA — — — — — — 1 — — 1
50 CLTC — — — — 1 — — — — 1
51 CT45S2 — — — — — 1 — — — 1
52 DCPS — — — — — — — 1 — 1
53 EEFSEC 1 — — — — — — — — 1
54 FNBP1 — 1 — — — — — — — 1
55 GAS7 — 1 — — — — — — — 1
56 GIGYF2 — — — — — — — — — 1
57 GMPS — — — — — — — 1 — 1
58 KIF2A — — — — — — 1 — — 1
59 LAMC3 — — — — 1 — — — — 1
60 LOC100131626 — — — — — — — — 1 1
61 ME2 — — — — — — — 1 — 1
62 MKL1 — — — 1 — — — — — 1
63 MYH11 — — — — — — — 1 — 1
64 NOX4 — — — — — — — 1 — 1
65 NRIP3 — 1 — — — — — — — 1
66 NUP153 — — — 1 — — — — — 1
67 PDS5A — — — — — — — 1 — 1
68 PFDN4 — — — 1 — — — — — 1
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Pediatric ALL (n= 313) displayed 139 AF4, 56 AF9, 56 ENL, 12
AF10, 16 AF6 and 6 EPS15 gene fusions. Another 31 MLL
rearrangements were characterized (21q22, AF17, LAF4, BCL9L,
CBL, FOXO3A, MAML2, MKL1, 5 cases (NA) with no der(11) and only
a reciprocal fusion allele, NUP153, PFDN4, PICALM, RUNDC3B, SEPT5,
SEPT11, TET1 and TNRC18).
Pediatric AML (n= 339) displayed 3 AF4, 132 AF9, 21 ENL, 66
AF10, 24 ELL, 6 MLL PTDs, 28 AF6 and 5 EPS15 gene fusions.
Another 54 MLL rearrangements have been diagnosed (6q27,
11q23.3, ABI1, ACACA, ACTN4, AF1Q, AF17, ARHGAP26, ARHGEF17,
BUD13, CLTC, DCP1A, FLNA, KLN1, LAMC3, an MLL gene-internal
deletion, MYO1F, 5 cases (NA) with no der(11) and only a
reciprocal fusion allele, NEBL, SEPT2, SEPT5, SEPT6, SEPT9, SEPT11,
TET1 and VAV1).
Adult ALL (n= 415) displayed 332 AF4, 9 AF9, 50 ENL, 1 AF10, 1
ELL, 1 MLL PTD, 9 AF6 and 4 EPS15 gene fusions. Additional 8 MLL
rearrangements were identified (11q23, ACTN4, CEP164, KIF2A,
MAML2, PRRC1, PTD and TET1).
Adult AML (n= 373) displayed 3 AF4, 90 AF9, 14 ENL, 33 AF10, 45
ELL, 98 MLL PTDs, 38 AF6 and 5 EPS15 gene fusions. Another 47
Table 1. (Continued )
# Direct TPG Infant Pediatric Adult Total
ALL AML Other ALL AML Other ALL AML Other
69 PRPF19 1 — — — — — — — — 1
70 PRRC1 — — — — — — — 1 — 1
71 RABGAP1 — — — — — 1 — — — 1
72 RUNDC3B — — — 1 — — — — — 1
73 SEPT2 — — — — 1 — — — — 1
74 SMAP1 — — — — — — — 1 — 1
75 TCF12 — — — — — — — 1 — 1
76 TOP3A — — — — — — — 1 — 1
77 VAV1 — — — — 1 — — — — 1
78 1p13.1 — — — — — — 1 — — 1
79 6q27 — — — — 1 — — — — 1
80 9p13.3 1 — — — — — — — — 1
81 11q24.3 — 1 — — — — — — — 1
82 21q22 — — — 1 — — — — — 1
83 MLL internal inv — — — — 1 — — — — 1
SUM 692 160 24 313 339 19 415 373 10 2345
Abbreviations: AML, acute lymphoblastic leukemia; AML, acute myeloid leukemia; DCAL, Diagnostic Center of Acute Leukemia; TPG, translocation
partner gene. All fusion genes that have been analyzed at the DCAL and their distribution between infant, pediatric and adult leukemia patients are shown.
Total numbers are given for each patient group separated in ALL, AML and other diseases. The most frequent fusion partner genes were separated from the
other genes that have been isolated less frequently by a line. Genes marked in bold represent out-of-frame MLL–X fusions.
Figure 1. Age distribution of investigated patients. The age distribution of all analyzed patients (n= 2345) is summarized. Upper part: diagram
displaying ALL and AML patients. Age at diagnosis was divided into infants (0–1 year), pediatric (1–18 years) and adult patients (418 years).
The number of ALL, AML and other patients is listed below. We also added the information about therapy-induced leukemia (TIL) patients, the
number of complex MLL rearrangements (CL) and specified the ‘non-ALL’ and ‘non-AML’ patients (MLL, MDS, lymphoma and other) in more
detail for each age group. The precise number of all patient cases is summarized on the right.
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MLL rearrangements were detected (1p13.1, 11q23, AF1Q, AKAP13,
AP2S2, ARHGEF12, C2CD3, CASP8AP2, CBL, CEP170B, DCPS, GMPS,
ME2, AF17, MYH11, 2 cases (NA) with no der(11) and only a
reciprocal fusion allele, NOX4, PDS5A, PICALM, SEPT5, SEPT6, SEPT9,
SMAP1, TCF12, TET1 and TOP3A).
On the basis of the above distribution, about 96% of all ALL
patients (n= 1420) were characterized by the fusion genes MLL–
AF4 (~57%), MLL–ENL (~18%), MLL–AF9 (~13%), MLL–AF10 (~4%),
MLL–EPS15 (~2%) and MLL–AF6 (~2%). About 83% of all AML
patients (n= 872) were characterized by the fusion genes MLL–AF9
(~30%), MLL–AF10 (~16%), MLL–ELL (~11%), MLL PTDs (~12%),
MLL–AF6 (~8%), MLL–ENL (~4%) and MLL–SEPT6 (~2%). These
results are in line with recently published data about the
frequency and distribution of different MLL fusion partner
genes.16–18 This updated information is quite important for
diagnosis and has already been used to establish a fast reverse-
transcription PCR-based multiplex screening method.19 Additional
information about the distribution of translocation partner genes
(TPGs) in major disease subgroups (different B-cell developmental
stages, T-ALL or French–American–British (FAB) M0–M7 for AML
patients) have been summarized in Supplementary Figures S1 and
S2. Here the different FAB classes in AML show a quite distinct
pattern of fusion genes with some of the major fusion partners
missing in distinct FAB groups M0–M7. For example, in FAB M0
AF4 and ELL are missing, in FAB M1 ENL is missing, in FAB M2 AF4,
AF10 and AF6 are missing and so on. In FAB class M6 and M7, only
certain fusion genes could be identified. In B-ALL stages, no such
exclusion patterns were observed, rather a shift for specific fusion
genes, while T-ALL is mainly composed of ENL and AF6 gene
fusions (see also below).
Breakpoint distribution according to clinical subtypes
We also investigated the distribution of chromosomal breakpoints
within the MLL breakpoint cluster region in all investigated clinical
subgroups. Briefly, the major breakpoint cluster region is localizing
between MLL exon 9 and MLL intron 11, where the majority of
patients (93.5%) had their individual breakpoints (n= 2192). Only
153 patients (6.5%) had their breakpoint outside of the major
breakpoint cluster region (Supplementary Figures S3–S5 and
Supplementary Table S6).
As the localization of breakpoints may have an impact on
cancer biology and clinical behavior, we started to analyze the
breakpoint distribution for all clinical subgroups and compared
them with the ‘mean distribution’ (MD) observed for all 2345
patients. We decided not to use a ‘random distribution model’ of
chromosomal breakpoints, because this is only based on the
length of each DNA region. However specific features in MLL
intron 9 (four Alu repetitive elements of which three are
transcriptionally active) and MLL intron 11 (sensitivity against
cytotoxic drugs, a DNase1 hypersensitive site,20 an apoptotic
cleavage site,21 an RNA polymerase II-binding site22 and
topoisomerase II-binding sites23) may account for a specific
increase of DNA double-stranded breaks due to specific molecular
features of the chromatin, or, breakpoints differ because of a
selection process for resulting MLL fusion proteins.
For our analyses, we subdivided the MLL breakpoint cluster
region into three subregions: (A) exon 9–intron 9 = 1761 bp; (B)
exon 10–intron 10 = 679 bp; (C) exon 11–intron 11–exon 12–intron
12 and exon 13 = 5026 bp. The observed ‘MD’ for these three MLL
breakpoint regions was A= 37.0%, B = 19.8% and C= 40.1% for all
2345 patients listed in Supplementary Table S7. In these analyses,
Figure 2. Classification of patients according to age classes and disease type. Top: frequency of most frequent TPGs in the investigated patient
cohort of MLL-r acute leukemia patients (n= 2345). This patient cohort was divided into ALL (left) and AML patients (right). Gene names are
written in black, percentages are indicated as white numbers. Fifty-three patients could not be classified into the ALL or the AML disease
types, respectively. Middle: TPG frequencies for the infant, pediatric and adult patient group. Bottom: subdivision of all three age groups into
ALL and AML patients. Negative numbers refer again to the number of patients that were neither classified to the ‘ALL’ nor to the ‘AML’
subgroup.
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Table 2. Overview about the MLL recombinome 2017
# Cytogenetic abnormality Breakpoint TPG References Leukemia type
A. MLL fusion in-frame
1 t(1;11)(p32;q23) 1p32 EPS15/AF1P Bernard et al. (1994) ALL, BAL, AML, CML
2 t(1;11)(q21;q23) 1q21 MLLT11/AF1Q Tse et al. (1995) AML, t-AML, ALL, t-ALL, BAL
3 t(2;11)(p23.3;q23) 2q23.3 ASXL2 Haferlach et al. (2016) t-AML
4 ins(2;11)(q11.2;q23) 2q11.2 AFF3/LAF4 von Bergh et al. (2003) ALL
5 t(2;11)(q33;q23) 2q33 ABI2 Coenen et al. (2012) AML
6 t(2;11)(q37;q23) 2q37 SEPT2 Cerveira et al. (2006) t-AML, AML, t-MDS
7 t(2;11)(q37.1;q23) 2q37.1 GIGYF2 Not published yet ALL
8 t(3;11)(p21;q23) 3p21 NCKIPSD/AF3P21 Sano et al. (2000) t-AML
9 t(3;11)(p21.1;q23) 3p21.1 DCP1A Meyer et al. (2008) ALL, AML
10 t(3;11)(q13.13;q23) 3q13.13 KIAS1524 Coenen et al. (2011) AML
11 t(3;11)(q24;q23) 3q24 GMPS Pegram et al. (2000) t-AML, t-MDS
12 t(3;11)(q28;q23) 3q28 LPP Daheron et al. (2001) t-AML
13 t(4;11)(p14;q23) 4p14 PDS5A Meyer et al. (2011) t-AML, AML
14 t(4;11)(p11;q23) 4p11 FRYL Hayette et al. (2006) t-ALL, t-AML, t-MDS
15 t(4;11)(q21.1;q23) 4q21.1 SEPT11/FLJ10849 Kojima et al. (2004) T-ALL, CML, t-ALL, t-AML
16 t(4;11)(q21;q23) 4q21 AF4/AFF1 Gu et al. (1992) ALL, t-ALL, BAL, AML
17 t(4;11)(q35.1;q23) 4q35.1 SORBS2/ARGBP2 Pession et al. (2006) AML
18 t(5;11)(q12.1;q23) 5q12.1 KIF2A Not published yet ALL
19 complex abnormalities 5q12.3 CENPK/FKSG14 Taki et al. (1996) AML
20 t(5;11)(q23.2;q23) 5q23.2 PRRC1 Douet-Guilbert et al. (2014) t-ALL
21 ins(5;11)(q31;q13q23) 5q31 AFF4/AF5Q31 Taki et al. (1999) ALL
22 t(5;11)(q31;q23) 5q31 ARHGAP26/GRAF Borkhardt et al. (2000) JMML
23 t(6;11)(q13;q23) 6q13 SMAP1 13 AML
24 t(6;11)(q15;q23) 6q15 CASP8AP2 Park et al. (2009) AML
25 t(6;11)(q21;q23) 6q21 FOXO3/AF6Q21 Hillion et al. (1997) t-AML, t-ALL
26 t(6;11)(q27;q23) 6q27 MLLT4/AF6 Prasad et al. (1993) T-ALL, AML, t-AML, ALL
27 t(7;11)(p22.1;q23) 7p22.1 TNRC18/KIAS1856 Meyer et al. (2008) T-ALL, ALL
28 t(7;11)(q11.23;q23) 7q11.23 CLIP2 Not published yet B-ALL
29 t(7;11)(q21.12;q23) 7q21.12 RUNDC3B 16 T-ALL
30 t(7;11)(q32.1;q23) 7q32.1 FLNC Haferlach et al. (2016) t-AML
31 t(9;11)(p13;q23) 9p13 CLTA Not published yet ALL
32 t(9;11)(p22;q23) 9p22 MLLT3/AF9 Nakamura et al. (1993) AML, t-AML, ALL, T-ALL, BAL
33 t(9;11)(q33.2;q23) 9q33.2 DAB2IP/AF9Q34 von Bergh et al. (2004) AML
34 t(9;11)(q34.11;q23) 9q34.11 RABGAP1 Not published yet ALL
35 ins(11;9)(q23;q34)inv(11)(q13)(q23) 9q34 FNBP1/FBP17 Fuchs et al. (2001) AML
36 t(9;11)(q34.12;q23) 9q34.12 LAMC3 15 t-AML
37 ins(10;11)(p12;q23) 10p12 NEBL Cóser et al. (2010) AML
38 ins(10;11)(p12;q23q13) 10p12 MLLT10/AF10 Chaplin et al. (1995) AML, t-AML, ALL, T-ALL, BAL
39 t(10;11)(p11.2;q23) 10p11.2 ABI1 Taki et al. (1998) AML
40 t(10;11)(q21;q23) 10q21 TET1/LCX Ono et al. (2002) AML, ALL
41 inv(11)(p15.3q23) 11p15.3 NRIP3 3 AML
42 inv(11)(q12.1q23) 11q12.1 BTBD18 Alonso et al. (2012) ALL
43 inv(11)(q12.2q23) 11q12.2 PRPF19 16 ALL
44 t(11;11)(q13.4;q23) 11q13.4 ARHGEF17 Teuffel et al. (2005) AML
45 inv(11)(q13.4q23) 11q13.4 C2CD3 15 AML
46 inv(11)(q14q23) 11q14 PICALM/CALM Wechsler et al. (2003) AML, ALL
47 inv(11)(q21q23) 11q21 MAML2 14 T-ALL,t-T-ALL, t-AML, t-MDS
48 del(11)(q23q23.3) 11q23.3 CBL Fu et al. (2003) AML, t-AML, ALL
49 del(11)(q23q23.3) 11q23.3 ARHGEF12/LARG Kourlas et al. (2000) AML, t-AML
50 del(11) )(q23q24.2) 11q24.2 DCPS 13 AML
51 t(11;12)(q23;p11.23) 12p11.23 ITPR2 Haferlach et al. (2016) t-MDS
52 t(11;12)(q23;q13.2) 12q13.2 SARNP/CIP29 Hashii et al. (2004) AML
53 t(11;14)(q23;q23.3) 14q23.3 GPHN Kuwada et al. (2001) AML, t-AML
54 t(11;14)(q23;q32.33) 14q32.33 CEP170B/KIAA0284 Burmeister et al. (2008) t-AML
55 t(11;15)(q23;q14) 15q14 KNL1/CASC5 Hayette et al. (2000) AML, t-MDS, ALL,
56 t(11;15)(q23;q15.1) 15q15.1 ZFYVE19/MPFYVE Chinwalla et al. (2003) AML
57 t(11;15)(q23;q21) 15q21 TCF12 Not published yet t-AML
58 t(11;15)(q23;q25.3) 15q25.3 AKAP13 16 t-AML
59 t(11;16)(q23;p13.3) 16p13.3 CREBBP/CBP Taki et al. (1997) t-MDS, t-AML, AML, t-ALL, t-CML
60 t(11;16)(q23;p13.11) 16p13.11 MYH11 16 AML
61 t(11;17)(q23;p13.1) 17p13.1 GAS7 Megonigal et al. (2000) t-AML
62 t(11;17)(q23;p11.2) 17p11.2 TOP3A Herbaux et al. (2012) AML
63 t(11;17)(q23;q12) 17q12 LASP1 Strehl et al. (2003) AML
64 ins(11;17)(q23;q21) 17q21 ACACA 13 AML
65 t(11;17)(q23;q21) 17q21 MLLT6/AF17 Prasad et al. (1994) AML, ALL
66 t(11;17)(q23;q23.1) 17q23.1 CLTC Not published yet AML
67 t(11;17)(q23;q25) 17q25 SEPT9/AF17Q25 Osaka et al. (1999) t-AML, AML, MDS, ALL
68 t(11;18)(q23;q21) 18q21 ME2 Szotkowski et al. (2015) t-AML
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Table 2. (Continued )
# Cytogenetic abnormality Breakpoint TPG References Leukemia type
69 t(11;19)(q23;p13.3) 19p13.3 MLLT1/ENL Tkachuk et al. (1992) ALL, T-ALL, AML, BAL, t-AL
70 t(11;19)(q23;p13.3) 19p13.3 ACER1/ASAH3 Lo Nigro et al. (2002) ALL
71 t(11;19)(q23;p13.3) 19p13.3 SH3GL1/EEN So et al. (1997) AML
72 ins(11;19)(q23;p13.3) 19p13.3 VAV1 15 AML
73 t(11;19)(q23;p13.2) 19p13.2 MYO1F Lo Nigro et al. (2002) AML
74 t(11;19)(q23;p13.1) 19p13.1 ELL Thirman et al. (1994) ALL, BAL, AML, t-AML
75 t(11;19)(q23;q13) 19q13 ACTN4 Burmeister et al. (2009) t-ALL, t-AML
76 t(11;20)(q23;q11.21) 20q11.21 MAPRE1 Fu et al. (2005) ALL
77 t(11;20)(q23;q13.2) 20q13.2 PFDN4 Not published yet T-ALL
78 t(11;22)(q23;q11.21) 22q11.21 SEPT5/CDCREL Megonigal et al. (1998) AML, T-ALL
79 t(11;22)(q23;q13) 22q13 MKL1 Not published yet ALL
80 t(11;22)(q23;q13.2) 22q13.2 EP300/P300 Ida et al. (1997) t-AML
81 t(X;11)(q13.1;q23) Xq13.1 FOXO4/AFX Parry et al. (1994) T-ALL, ALL, t-ALL,CLL, AML
82 ins(X;11)(q24;q23) Xq24 SEPT6 Borkhardt et al. (2001) AML
83 ins(X;11)(q26.3;q23) Xq26.3 CT45S2 Cerveira et al. (2010) BAL
84 ins(11;X)(q23q28q13.1) Xq28 FLNA De Braekeleer et al. (2009) AML
B. MLL fusion not in-frame
1 t(3;11)(p21.3;q23) 3p21.3 SACM1L 34 N/A
2 t(3;11)(q21.3;q23) 3q21.3 EEFSEC/SELB 13 ALL
3 t(6;11)(p22.3;q23) 6p22.3 NUP153 Not published yet ALL
4 inv(11)(p15.5q23) 11p15.5 AP2S2 16 AML
5 complex 11q14 NOX4 Not published yet ALL
6 t(11;15)(q23.3;q21) 11q23.3 LOC100131626 33 MDS
7 inv(11)(q23.3q23) 11q23.3 BUD13 16 AML
8 del(11)(q23q23.3) 11q23.3 CEP164 16 t-ALL
9 del(11)(q23q23.3) 11q23.3 BCL9L 14 ALL
10 t(2;11;19)(p23.3;q23;p13.3) 19p13.3 LOC100128568 15 AML
C. No partner gene fused to 50-MLL gene
1 t(1;11)(p13.1;q23) 1p13.1 16 PMF
2 t(6;11)(q27;q23) 6q27 Not published yet AML
3 t(9;11)(p13.3;q23) 9p13.3 16 t-ALL
4 t(11;11)(q23;q23.3) 11q23.3 16 ALL, AML
5 t(11;11)(q23;q24.3) 11q24.3 16 AML
6 t(11;21)(q23;q22) 21q22 16 t-ALL
D. Not characterized at the molecular level (published by others)
1 t(1;11)(p36;q23)
2 t(1;11)(q31;q23)
3 t(1;11)(q32;q23)
4 t(2;11)(p21;q23)
5 t(2;11)(q37;q23)
6 t(3;11)(p13;q23)
7 t(4;11)(p11;q23)
8 t(6;11)(q13;q23)
9 t(7;11)(p15;q23)
10 t(7;11)(q22;q23)
11 t(7;11)(q32;q23)
12 t(8;11)(q11;q23)
13 t(8;11)(q21;q23)
14 t(8;11)(q24;q23)
15 t(9;11)(p11;q23)
16 t(9;11)(q33;q23)
17 t(10;11)(q25;q23)
18 t(11;11)(q11;q23)
19 t(11;11)(q13;q23)
20 t(11;11)(q21;q23)
21 t(11;12)(q23;p13)
22 t(11;12)(q23;q13)
23 t(11;12)(q23;q24)
24 t(4;13;11)(q21;q34;q23)
25 t(11;14)(q23;q11)
26 t(11;14)(q23;q32)
27 t(11;15)q23;q15)
28 t(11;17)(q23;q11)
29 t(11;17)(q23;q23)
30 t(11;18)(q23;q12)
31 t(11;18)(q23;q23)
32 t(11;20)(q23;q13)
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all patients were investigated for their fusion partner gene in
correlation with age at diagnosis, gender, patient group, therapy-
induced leukemia, complex genetic rearrangements, origin of
patient and breakpoint distribution. Here a significant deviation
from the ‘MD’ was observed for AF1Q, AF6, AF10, ENL, EPS15, SEPT6,
SEPT9, AF17 and MLL PTDs. The fusion partner genes ENL and
SEPT6 had preferentially MLL intron 11 breaks, while all others
tend to bear MLL intron 9 recombination events. Of interest, also
therapy-induced acute leukemias differ significantly in their ‘MD’,
with a tendency for MLL intron 11 breaks.
A detailed analysis for the most frequent MLL fusion partner
genes is depicted in Supplementary Table S8. Here we separated
according to fusion partners and patient subgroup (infant I,
pediatric P and adult A) with regard to several other parameters
such as age, gender, therapy-induced, complex translocation,
origin and disease type. The overall breakpoint distribution of all
seven most frequent genetic aberrations with more than 2000
patients was not significantly deviating from the MD of all
patients. However, significant changes were observed for patient
subgroups bearing chromosomal translocations to AF4 (I and A),
AF9 (A), ENL (I and P), AF10 (P), ELL (I, P and A), AF6 (I, P and A) and
MLL PTD patients (P and A). This clearly demonstrates that certain
fusion genes have a selective preference for distinct breakpoints,
most likely because of the resulting function of a given fusion
protein. As an example, AF6 fusions in ALL and AML patients are
mostly occurring in MLL intron 9 (or even upstream), while infant
AF4 and infant/pediatric ENL fusions tend to have breakpoints
within MLL intron 11. Similar observations were made for the more
rare fusion partner AF1Q (significantly toward MLL intron 9), AF17
(significantly toward MLL introns 8 and 9), EPS15 (significantly
toward MLL intron 11 in adult patients), SEPT6 (significantly
toward MLL intron 11 in pediatric and adult patients) and SEPT9
(significantly toward MLL introns 7–9).
To evaluate these data further, we correlated the breakpoint
distribution with the age of patients. We have done so for ALL and
AML patients (Supplementary Figures S9 and S10). These analyses
revealed that the disease subtypes (ALL and AML) divide patients
into two groups (ALL more in MLL intron 11 breakpoints; AML
more in MLL intron 9 breakpoints). However, these breakpoint
tendencies seem to change with age. Thus, young patients usually
display MLL intron 11 breakage, while older patients have more
breaks in MLL intron 9. This is true for all investigated subgroups
(AF4, ENL and AF9) where we had enough patients to perform this
type of analysis and to obtain a significant result. Vice versa, young
AML patients usually prefer MLL intron 9 breakage, while older
patients have more breaks in MLL intron 11. This has been done
also for the AF9, AF10 and ELL subgroups. The cross-over points
were 10–14 years in ALL patients and 75 years in AML patients.
MLL–ELL patients within the AML group are somehow different
from all other subgroups because they start very early on with a
preference for MLL intron 11 (all patients above 1 year of age) and
display no cross-over point. These breakpoint preferences and
their change with age are indicating that two different molecular
mechanisms are driving MLL rearrangements: one is a
transcription-coupled hot spot that is quite sensible for external
cytotoxic triggers (MLL intron 11), while the other is presumably
based on transcriptionally active ALU repeats where POL III and
POL II transcription is causing torsional DNA stress.
Another important point is the outcome of patients that is linked
to the distribution of chromosomal breakpoints within the MLL
breakpoint cluster region.24 Basically, the outcome of leukemia
patients with breakpoints in MLL intron 11 was worse compared to
those patients with upstream breakpoints. A rational explanation for
this observation came from functional studies of the plant
homeodomain (PHD) domain of the MLL protein, encoded by
MLL exons 11–16 (Supplementary Figure S11). This domain is built
up by PHD1, PHD2 and an enhanced PHD3. The first three PHD
domains are separated by the adjacent bromodomain and another
enhanced PHD4. PHD3 has an important dual function, because it
either binds to the CYP33/PPIE protein25,26 or to methylated lysine-4
residues of histone H3.27 Binding of PHD3 to H3K4me2/3 peptides is
greatly enhanced by the adjacent bromodomain,28 but binding of
the prolyl-peptidyl isomerase CYP33/PPIE confers a cis–trans
isomerization of proline-1665. This enables binding to BMI1 and
associated repressor proteins (HDAC/CBX4/KDM5B). This molecular
switch determines the human MLL protein of being a transcriptional
activator/maintenance factor or a transcriptional repressor. Note-
worthy, PHD2 and PHD3 also bind to E3-ligases (CDC34 and ASB2,
respectively), which control the steady-state stability of the MLL
protein.29,30 As shown recently by our group, breakpoints within
MLL intron 11 destroy the dimerization capacity of the PHD1–3
domain.31 This also disables binding to the BMI1 repressor
complex.32 Thus, a breakpoint within MLL intron 11 has functional
consequences for the resulting fusion proteins, which may explain
the clinical finding of the altered outcome.24
The MLL recombinome
On the basis of the results obtained in the present and previous
studies,13–16 a total of 84 direct TPGs and their specific breakpoint
regions have now been identified, all of which generate an in-
frame MLL fusion protein (Table 2A). Additional 10 MLL fusions
were characterized that were fused out of frame to translocation
partner genes (Table 2B). In the latter cases, alternative splicing
may still allow to generate an MLL-fusion protein, however, this
was not investigated here. Another 6 loci have been cloned where
the 5ʹ-portion of MLL was not fused to another gene (Table 2C). 3ʹ-
Race and reverse-transcription PCR experiments with several exon
combinations were performed to identify potential fusion
transcripts. But no in-frame fusion RNAs could be identified.
Therefore, these 16 unusual MLL rearrangements—where neither
any dimerization nor a transcriptional activation domain is present
—probably represent a subclass of MLL abnormalities, which have
per se no or only a weak ability to transform hematopoietic cells
and are only identified in the context of other genetic
abnormalities in hematopoietic stem cells.33,34
In 31 additional cases we were not able to identify a der(11)
fusion gene at all. This could be either attributed to a technical
Table 2. (Continued )
# Cytogenetic abnormality Breakpoint TPG References Leukemia type
33 t(11;21)(q23;q11)
34 t(Y;11)(p11;q23)
35 t(X;11)(q22;q23)
Abbreviations: AML, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BAL, bilineal acute leukemia; CML, chronic myelogenous leukemia; DCAL,
Diagnostic Center of Acute Leukemia; JMML, juvenile myelomonocytic leukemia; MLL, mixed lineage leukemia; t-ALL, therapy-related ALL; t-AML, therapy-
related AML; t-MDS, therapy-related MDS; TPG, translocation partner gene. List of the cytogenetic localization of all yet-characterized direct TPGs (n= 94), the
gene name, the appropriate reference and observed disease type. Genes marked as ‘not published yet’ are completely new. All references in italics have been
identified at the DCAL during the last decade. In addition, 6 cloned gene loci and 35 cytogenetic chromosome loci have been identified.
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problem (for example, a too long genomic fragment) or to the fact
that no der(11) exists in these few patients. However, in 22/31
cases we successfully identified a reciprocal MLL fusion allele,
while 9 cases carried no detectable direct or reciprocal fusion
gene. This subgroup (n= 31) was included in the group of
‘complex MLL rearrangements’ (n= 247) because of the extending
class of ‘reciprocal MLL fusion genes’ (Supplementary Table S12).
Within this group of patients with complex MLL rearrangements, a
total of 32 reciprocal MLL fusions represent in-frame fusions
(marked in red in Supplementary Table S12), while 215 fusions
were out-of-frame fusions at the genomic DNA level (88 gene loci/
127 partner genes; shown in black in Supplementary Table S12).
Finally, there were still 35 chromosomal translocations of the
human MLL gene that were characterized in the past by
cytogenetic methods, but that were never analyzed at the
molecular level (Table 2D). Thus, the MLL recombinome to date
comprises 94 different ‘direct TPGs’ (decoding the MLL N
terminus) and 6 different 5ʹ-MLL genes fused only to genomic
DNA. On the other hand we have now 247 ‘reciprocal TPGs’
(bearing the MLL C terminus) that are deriving from complex
rearrangements with already-known ‘direct TPGs’. It is noteworthy
that nearly all of these reciprocal MLL fusion (243 out of 247) are
per se able to express only the 3ʹ-MLL portion, named MLL*, due to
a gene internal promoter located upstream of MLL exon 12.22
Novel translocation partner genes
Apart from the many new MLL fusion genes that have already
been discovered at the DCAL and published in the last decade
(Tables 2a–c; n= 40), we present additional 11 novel TPGs (marked
as ‘not published yet’): GIGYF2 (GRB10-interacting GYF; 2q37.1;
1299 aa); KIF2A (kinesin heavy chain member 2A; 5q12.1; 706 aa);
CLIP2 (CAP-GLY domain-containing linker protein 2; 7q11.23; 1046
amino acids (aa)); CLTA (clathrin, light chain A; 9p13.3; 248 aa);
RABGAP1 (RAB GTPase-activating protein 1; 9q33.2; 1069 aa);
TCF12 (transcription factor 12; 15q21.3; 682 aa); CLTC (clathrin,
heavy chain; 17q23.1; 1,675 aa); PFDN4 (prefoldin subunit 4;
20q13.2; 134 aa); MKL1 (megakaryoblastic leukemia (translocation)
1; 22q13.1; 931 aa); NUP153 (nucleoporin 153 kDa; 6p22.3; 1475
aa); and NOX4 (NADPH oxidase 4; 11q14.3; 578 aa).
The Drosophila GIGYF2 protein ortholog was shown to be a
modulator of autophagy that controls neuron and muscle
homeostasis.35 GIGYF2 binds directly to AGO2 and is involved in
siRNA-mediated post-transcriptional silencing.36 A quite specific
feature of GIGYF2 is to build a complex together with eIF4E and
ZNF598 to selectively block the process of translation of distinct
capped mRNAs.37 Several papers have linked GIGYF2 also to
Parkinson’s disease, however, these data are so far not sufficiently
significant.
KIF2A is a member of the kinesin-13 family and involved in
spindle assembly at the metaphase I–anaphase I transition of
oocytes.38,39 Moreover, genetic mutations in the motor domain of
this protein is associated with cortical malformation syndromes
such as microcephaly.40 Vice versa, overexpression of KIF2A has
been diagnosed in different cancers, because KIF2A expression
and phosphorylation influences microtubuli dynamics, which is
important for tumor cell migration and metastasis.41
CLIP2 has been discovered as overexpressed biomarker after
radiation in papillary thyroid carcinomas, usually accompanied by
a gain of chromosome band 7q11.42 This disease has been
frequently diagnosed as the main consequence of the Chernobyl
accident.
CLTA, also named clathrin light chain A, is involved in vesicle
trafficking and endocytosis. However, a recent paper demon-
strated that CLTA has a role on the migration of tumor cells.43 This
is in part due to the fact that CLTA interacts with Huntingtin-
interacting protein, involved in the regulation of the actin
cytoskeleton. Upon depletion of clathrin light chains a steady-
state downregulation of β1-integrins was observed because of
defects in vesicle recycling.
RABGAP1 is highly specific for RAB6A and has a role in
microtubule nucleation at the centrosome. It also participates in a
RAB6A-mediated pathway involved in the metaphase–anaphase
transition (Mad2-spindle checkpoint).44
TCF12, also known as HeLa E-box binding protein, is quite
interesting as it controls the osteogenic differentiation of
mesenchymal stem cells in the bone marrow.45 This basic helix–
loop–helix transcription factor was also found to be mutated in
anaplastic oligodendroglioma.46 TCF12 is able to bind to TWIST1
and involved in the early differentiation pathways of thymic T cells
(DN3-4DN4 and ISP-4DP).47
CLTC has been identified in complex chromosomal rearrange-
ments causing the expression of the CLTC–ALK fusion in blastic
plasmacytoid dendritic cell neoplasm.48 A more recent work has
found CLTC mutations are associated with neuronal malformations
and intellectual developmental delays.49 This is due to the fact
that clathrin heavy and light chains (CLTA and CLTC) are involved
in vesicle trafficking, vesicle recyling and neurotransmitter release.
PFDN4 has been linked to colorectal cancer, however, inversely
correlated with outcome (low expression has poorer outcome). A
knockdown of this gene was correlated with increased cell growth
and invasiveness.50
MKL1 interacts with the transcription factor myocardin, a key
regulator of smooth muscle cell differentiation. The encoded
protein is predominantly nuclear and may help transduce signals
from the cytoskeleton to the nucleus. This gene is involved in a
specific translocation event that creates a fusion of this gene and
the RNA-binding motif protein-15 gene. This specific t(1;22)(p13;
q13) translocation has been associated with the development of
acute megakaryocytic leukemia.51
NUP153 s a highly versatile protein, involved in nuclear pore
functions, pore architecture, nuclear import and export, de novo
pore formation after mitosis and destruction of NUP153 during
apoptosis.52
NOX4 is NADPH oxidase 4 that is important in the regulation of
glycolysis and glutamate metabolism. Disruption of NOX4 by
CRISPR/Cas9 is inhibiting cell growth of HeLa cells, indicating that
NOX4 is quite important as metabolic regulator in tumor cells.53
NOX4 has been identified in many tumors as a relevant gene.
T-ALL cases
A tiny fraction of investigated patients were diagnosed with a T-ALL
(n=59) (Supplementary Figure S13). This group of patients is mainly
characterized by MLL fusion with AF6 (n=23) and ENL (n=22).
Other fusions were AF4, AF9, AF10, MAML2, PFDN4, RUNDC3B, SEPT5,
SEPT11, TNRC18 and 1 reciprocal USP20–MLL fusion. Only in the
cohort of MLL–AF6 patients, quite unusual MLL breakpoints were
observed (n=4), where the chromosomal breakpoint in the MLL
gene was diagnosed within intron 21 and 23. This is quite important
because such a far away downstream breakpoint includes the
complete PHD1–3, the bromodomain as well as the complete
enhanced PHD4 domain of MLL into the fusion protein with AF6
(Supplementary Figure S11). These additional 581 amino acids
could be an important hint for the importance of these MLL
domains in T-ALL. The PHD1–3 and bromodomain exert important
regulatory functions to the MLL N terminus, such as chromatin
reading, protein stability or CYP33 binding. In the latter case,
binding of the BMI1 repressor complex will reverse the function of
the MLL–AF6 fusion by repressing gene transcription. This is quite
interesting and provides a new research aspect for MLL–AF6.
Therapy-induced leukemia cases
We also investigated the therapy-induced patient cases (n= 110;
Supplementary Table S14). The dominant partner genes are AF9
(n= 41), ELL (n= 11), AF4 (n= 11) and ENL (n= 10). All other fusions
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(n= 23) have been identified one to four times. To our surprise, the
AF9 cases were shifting from MLL intron 9 breaks to MLL intron 11
breaks. Some MLL fusions can only be found in therapy-induced
acute leukemia and not in patients with de novo diseases: ACTN4;
AKAP13; ARHGEF12; FOXO3A; GMPS; LAMC3; ME2; PDS5A; PRRC1;
and TCF12. As expected, therapy-induced acute leukemias were
only diagnosed in pediatric and adult patients, not in infants.
Spliced fusions
Spliced fusions are rare events except for the ENL fusion gene
(n=302). In the latter cases, about 50% of all breakpoints localize far
upstream of ENL exon 1 (n=153; Supplementary Table S15). In these
cases, no reciprocal fusion protein can be made, only an MLL–ENL
fusion transcript.54 For the other cases, a similar scenario was found.
In all these cases, a 3ʹ-terminal truncated MLL was recombined
upstream of PRPF19 (1 out of 1 case), ELL (8 out of 97 cases), MYO1F
(1 out of 4 cases), EPS15 (9 out of 38 cases), AF4 (1 out of 839 cases),
AF6 (3 out of 95 cases) and AF9 (2 out of 449 cases). A total of 180
cases were identified that show this unusual peculiarities.
DISCUSSION
Here we present an update of the ‘MLL recombinome’ associated
with different hematologic malignancies, and in particular with
acute leukemia (ALL and AML). All our analyses were performed by
using small amounts of genomic DNA that were isolated from
bone marrow or peripheral blood samples (n= 2345) of leukemia
patients. In some cases, we analyzed cDNA from a given patient to
validate the presence of MLL spliced fusions, or to investigate
alternative splicing of RNA generated from the investigated MLL
fusion genes. The results of this study allow to draw several
conclusions.
The applied long-distance inverse PCR technique allowed to
identify direct and reciprocal MLL fusions, MLL gene-internal
duplications, chromosome 11 inversions, chromosomal 11 dele-
tions and the insertion of chromosome 11 material into other
chromosomes, or vice versa, the insertion of chromatin material of
other chromosomes into the MLL gene. It is noteworthy to
mention that no other technique (for example, next-generation
sequencing) displays such a high identification of chromosomal
fusion sites so far. Even paired-end mRNA analysis by next-
generation sequencing has a discovery rate of 60–70% only,
however, RNA-based technologies do not provide the patient-
specific chromosomal fusion sequences that could be used for
MRD analyses. Thus, this ‘old-fashioned’ method is still state of the
art and will be used also in the future to gain additional
information of the MLL recombinome.
Moreover, we extended our knowledge on complex MLL
rearrangements (n=247) leading to a large collection of reciprocal
MLL fusions (Supplementary Table S12). About 13% represent in-
frame fusions that can be readily expressed into reciprocal fusion
proteins. All other represented out-of-frame fusions with either a
chromosomal locus or a reciprocal TPG. Out-of-frame fusions such
as IKZF1–MLL, PBX1–MLL or JAK1–MLL most likely represent a
situation where such TPGs were destroyed, creating a typical loss-
of-function situation. However, even those out-of-frame MLL fusions
still allow to transcribe and express a 5ʹ-truncated MLL protein,
termed MLL*.22 This shorter version of MLL has no ability to bind
Menin1, LEDGF or MYB, but still carries all enzymatic functions
necessary to carry out H4K16 acetylations by the associated MOF
protein or H3K4 methylation by the SET domain complex.
The analysis of 2345 MLL fusion alleles led to the discovery of 51
novel TPGs in the past 12 years, of which 40 have already been
described (Tables 2a–c). Eleven TPGs are completely new and
have not been published yet. Together with 49 MLL fusions that
have been described by others, we can present today a total of 94
MLL fusions that have been characterized at the molecular level
and 6 MLL translocations to different genetic loci (with no obvious
gene fusion). All these MLL fusions provide a rich source for future
analyses of oncogenic MLL protein variants. We have summarized
all yet-known MLL fusion partner genes in Figure 3, according to
their disease type/subtype in which they have been diagnosed.
According to our data, the 7 most frequent rearrangements of
the MLL gene differ significantly in the cohorts of infant, pediatric
and adult leukemia patients. We also observed significant
tendencies that correlate with fusion genes, gender or age at
diagnosis. As an example MLL–AF10 (P= 0.0024) occur more
frequently in the male group of patients, while females were more
affected by MLL–AF4 fusions (P= 0.00576). The most striking
Figure 3. Classification of all yet known fusion partner genes by disease. All TPGs identified were grouped by their diagnosed disease type.
Genes have been diagnosed in ALL, t-ALL, t-AML, AML, T-ALL, MLL, bilineal acute leukemia (BAL), MDS, t-MDS, chronic myelogenous leukemia
(CML), t-CML, juvenile myelomonocytic leukemia (JMML) and lymphoma. Genes in the intersection belong to two different groups. Bold-
marked TPGsb are the most frequent ones.
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finding was that breakpoint distributions differ significantly when
concerning distinct TPGs and age groups. It is well-known that
breakpoints in infants occur more frequently in MLL intron 11. We
could validate this finding for infants with MLL–AF4, infant/
pediatric patients with MLL–ENL fusions and pediatric/adult
patients with MLL–ELL fusions. However, we observed a contrary
situation in adult patients with MLL–AF9 or pediatric patients with
MLL–AF10 fusions. Quite surprising was the breakpoint distribution
for MLL–AF6 fusions that displayed a clear preference for MLL intron
9 recombinations. Again, these deviations from the observed mean
breakpoint distribution (MD) are an argument for differences in the
biology of the resulting fusion proteins with respect to oligomeriza-
tion or factor-binding dependency. Alternatively, it may reflect
differences in the biology of transformed cell types, or, reflect
different situations during the onset of these translocations (in utero
exposition with poisons vs postnatal acquirement).
An important translational aspect of this study is the establish-
ment of patient-specific DNA sequences that can be used for
monitoring MRD by quantitative PCR techniques. Because of the
fact that a given MLL fusion allele is genetically stable and a mono-
allelic marker for each tumor cell, a more reliable quantification
and tracing of residual tumor cells becomes possible. For each of
these 2384 acute leukemia patients at least one MLL fusion allele
was identified and characterized by sequencing. Several prospec-
tive studies were already initiated and first published data verified
the reliability of these genomic markers for MRD monitoring.4–7
Therefore, the use of these MRD markers will contribute in the future
to a better stratification of leukemia patients, which will help to
further improve the outcome. In particular, for infant ALL patients,
due to the relatively low numbers of potential IG/TR MRD-PCR
targets, the availability of an MLL fusion DNA rearrangement has a
high impact for the clinical application of MRD monitoring.
The analysis of the MLL recombinome allows to classify MLL
fusion partner genes into functional categories. As discussed
above, only very few TPGs are recurrently identified with a
significant frequency. On the basis of the present study these TPGs
are AF4, AF6, AF9, AF10, ELL and ENL. At least for the AF4, AF9, ENL
and AF10 proteins exist a functional correlation, as all these
proteins are organized within a protein complex (or different
subcomplexes) that affect transcriptional elongation. AF4 is the
docking platform for AF9 or ENL, which both interact (via AF10) to
DOT1L.55,56 DOT1L enable methylation of lysine-79 residues of
histone H3 proteins, a prerequisite for the maintenance of RNA
transcription57,58 AF4 binds with its N-terminal portion to the
P-TEFb kinase that phosphorylates the largest subunit of RNA
polymerase II, DSIF, the NELF complex and UBE2A. This converts
RNA POL A into POL E and allows gene transcription.59 As a result,
increased and extended H3K79 methylation signatures seem to
accompany the presence of several fusion proteins (MLL–AF4,
AF4–MLL, MLL–AF9, MLL–ENL, MLL–AF10 and MLL–AF6),60 while
an additional increase in H3K4 methylation was only demon-
strated by the presence of the reciprocal AF4–MLL59 that causes
proB ALL in C57Bl6 mice61 and was shown to cooperate with the
RUNX1 protein.62 Thus, all the major MLL fusions share a common
pathway, which is not only functionally related but offers new and
interesting venues to develop new drugs against these leukemias,
for example, by the development of DOT1L inhibitors.63 The fusion
proteins MLL–ENL, MLL–AF9 and MLL–AF10 recruit thereby the
AF4 complex, while the reciprocal AF4–MLL fusion protein is able
to perform exactly the same actions on RNA polymerase II and
DOT1L. Thus, future therapies addressing either the inhibition of
DOT1L, P-TEFb, or blocking the interaction of the MLL N terminus
with MENIN1/LEDGF/MYB are promising new ways to address
these leukemias. In addition, the inhibition of Taspase1 would
help to inactivate the AF4–MLL fusion protein, as the uncleaved
fusion protein is rapidly degraded by SIAH1 and SIAH2.64
For all the other MLL fusion partners identified so far, a
systematic classification about their function(s) has been described
in great detail recently.65 However, further functional studies are
necessary to study the mechanisms that are involved or causative
for their leukemogenic activity. Such studies will provide the basis
for developing new therapeutic strategies in the future.
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